Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John Rossi

Showing results (81-90 of 85) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 85 results.
Cytotherapy|February 27, 2022
Need for aligning the definition and reporting of cytokine release syndrome (CRS) in immuno-oncology clinical trialsMark D Stewart, Bruce McCall, Marcelo Pasquini, et al.
Haematologica|October 20, 2022
Three-year results from phase I of ZUMA-4: KTE-X19 in pediatric relapsed/refractory acute lymphoblastic leukemiaAlan S Wayne, Van Huynh, Nobuko Hijiya, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 15, 2017
Lymphoma Remissions Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With High Serum Interleukin-15 LevelsJames N Kochenderfer, Robert P T Somerville, Tangying Lu, et al.
Genes & Development|November 10, 2017
RANK rewires energy homeostasis in lung cancer cells and drives primary lung cancerShuan Rao, Verena Sigl, Reiner Alois Wimmer, et al.
The New England Journal of Medicine|December 12, 2017
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell LymphomaSattva S Neelapu, Frederick L Locke, Nancy L Bartlett, et al.
Pageof 9

Showing results (81-90 of 85) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 85 results.
Cytotherapy|February 27, 2022
Need for aligning the definition and reporting of cytokine release syndrome (CRS) in immuno-oncology clinical trialsMark D Stewart, Bruce McCall, Marcelo Pasquini, et al.
Haematologica|October 20, 2022
Three-year results from phase I of ZUMA-4: KTE-X19 in pediatric relapsed/refractory acute lymphoblastic leukemiaAlan S Wayne, Van Huynh, Nobuko Hijiya, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 15, 2017
Lymphoma Remissions Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With High Serum Interleukin-15 LevelsJames N Kochenderfer, Robert P T Somerville, Tangying Lu, et al.
Genes & Development|November 10, 2017
RANK rewires energy homeostasis in lung cancer cells and drives primary lung cancerShuan Rao, Verena Sigl, Reiner Alois Wimmer, et al.
The New England Journal of Medicine|December 12, 2017
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell LymphomaSattva S Neelapu, Frederick L Locke, Nancy L Bartlett, et al.
Pageof 9